

PharmaMatrix — Company fact sheet

Snapshot

Company: PharmaMatrix Inc.

Stage: Clinical (Phase 1)

Lead asset: CCI-001

Indications: Bladder cancer (lead), breast cancer (expansion)

Trial ID: NCT04823897

IP: Patents granted by USPTO (2016), CIPO (2017), EPO (2017)

Mechanism

Selective binding to β III-tubulin via the colchicine binding site. Disrupts microtubule formation, arrests mitosis in cancer cells, and triggers apoptosis — while sparing healthy tissue.

Leadership & science

Principal investigator: Jack A. Tuszynski, Ph.D., D.Sc. — Allard Endowed Research Chair, Department of Experimental Oncology, University of Alberta. Multidisciplinary team across physics, chemistry, biology and oncology, with international collaborators in 6+ countries.